Factor VIII
This protein circulates in the bloodstream in an inactive form, bound to another molecule called von Willebrand factor, until an injury that damages blood vessels occurs.Transcript variant 1 encodes a large glycoprotein, isoform a, which circulates in plasma and associates with von Willebrand factor in a noncovalent complex.Transcript variant 2 encodes a putative small protein, isoform b, which consists primarily of the phospholipid binding domain of factor VIIIc.[9] People with high levels of factor VIII are at increased risk for deep vein thrombosis and pulmonary embolism.[24] In the 1980s, some pharmaceutical companies such as Baxter International and Bayer sparked controversy by continuing to sell contaminated factor VIII after new heat-treated versions were available.[25] In the early 1990s, pharmaceutical companies began to produce recombinant synthesized factor products, which now prevent nearly all forms of disease transmission during replacement therapy.Factor VIII was first discovered in 1937, but it was not until 1979 that its purification by Edward Tuddenham, Frances Rotblat and coworkers led to the molecular identification of the protein.
Factor VIII (medication)AliasesHomoloGeneGeneCardsX chromosome (human)RNA expressionGene ontologyOrthologsEntrezEnsemblUniProtPubMedWikidatablood clottingproteinhemophilia Ableeding disordersinusoidal cellsendothelialvon Willebrand factorinjuryblood vesselsblood coagulationfactor IXaphospholipidsfactor Xglycoproteindeep vein thrombosispulmonary embolismFactor VIIIWHO Model List of Essential Medicineshealth systemX chromosomeintronshomologousfactor Vceruloplasminphospholipiddiscoidin domaincofactorendotheliumtransplantationhepatocytes
noncovalentthrombincoagulation cascadefactor Vafibrinogenfibrinpolymerizesfactor XIIIhalf-lifeproteolyticallyprotein Chemophiliacshemostasisrecombinant FVIIaimmunohistochemistryContaminated haemophilia blood productsBaxter Internationalcontaminated factor VIIIFood and Drug AdministrationrecombinantEdward TuddenhamFrances RotblatRalph KekwickEdward ShanbromRyan WhiteBibcodeThe TimesMedical Subject HeadingsPDBe-KBCoagulation factorsvon Willebrand factor (vWF)Platelet membrane glycoproteinsGlycoprotein Ib (GPIb)Glycoprotein IX (GP9)Glycoprotein IIb/IIIaGPIIIaGlycoprotein VI (GPVI)High-molecular-weight kininogen (HMWK)BradykininPrekallikreinKallikreinFactor XII (Hageman factor)Factor XIFactor IXFactor III (tissue factor)Factor VIIProthrombin (factor II)Thrombin (factor IIa)Fibrinogen (factor I)Fibrin (factor Ia)Anticoagulant factorsAntithrombin (inhibits FII, FIX, FX, FXI, FXII)Protein C (inhibits FV, FVIII)Protein S (cofactor for protein C)Protein Z (inhibits FX)Protein Z-related protease inhibitor (ZPI) (inhibits FX, FXI)Tissue factor pathway inhibitor (TFPI) (inhibits FIII)Fibrinolytic factorsPlasminogenPlasminTissue plasminogen activator (tPA)UrokinasePlasminogen activator inhibitor-1 (PAI-1)Plasminogen activator inhibitor-2 (PAI-2)α2-Antiplasminα2-MacroglobulinThrombin-activatable fibrinolysis inhibitor (TAFI)Coagulation markersPlatelet activationPlatelet factor 4 (PF4)β-Thromboglobulin (β-TG)Thrombin generationProthrombin fragment 1+2 (F1+2)Thrombin–antithrombin complex (TAT)Activated protein C–protein C inhibitor (APC–PCI)Fibrin generationFibrinopeptide A (FpA)Fibrinopeptide B (FpB)Fibrin monomers (FM)FibrinolysisPlasmin-α2-antiplasmin complex (PAP)D-Dimer (DD)